Biorestorative Therapies Inc (BRTX) Stock Price, Quote & News

Company Profile

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral di...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 760 8100

Website: www.biorestorative.com

Address:

40 Marcus Drive, Suite 1, Melville, United States

_Burn_ Apr. 24 at 4:14 PM

$BRTX https://x.com/BioRestorative/status/2047674445515669998?s=20

0 · Reply

focafoca99 Apr. 23 at 9:33 PM

$BRTX updated its corporate presentation for use in investor meetings and conferences.

1 · Reply

MoonSprinkle Apr. 22 at 11:57 PM

$BRTX Positive clinical progress

2 · Reply

_Burn_ Apr. 22 at 2:45 PM

$BRTX https://x.com/BioRestorative/status/2046961905320014138?s=20

0 · Reply

Pamella3897 Apr. 22 at 1:43 PM

$BRTX !!!!!!

1 · Reply

DARKP00L Apr. 21 at 12:24 PM

$BRTX 08:06 on Apr. 21 2026 BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform #tradeideas

0 · Reply

MrTicker Apr. 21 at 12:06 PM

$BRTX BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform BENZINGA 7:06 AM ET 4/21/2026

0 · Reply

MrTicker Apr. 21 at 12:05 PM

$BRTX BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform GLOBENEWSWIRE 7:00 AM ET 4/21/2026

0 · Reply

Pamella3897 Apr. 20 at 9:38 PM

$BRTX Post-Effective Amendment No. 1 to Form S-1 Up to 15,285,715 shares underlying warrants BUYER BEWARE!!! HUGE OFFERING IMMINENT!!!

1 · Reply

FillSniper42 Apr. 17 at 7:57 PM

ABTS stock will 5X from here back to $5-$10+ cheapest mining play on the market - Bottomed out near all time low at 1.30 and was 10+ a few months ago - Only droped because of the crypto selloff..now with crypto reversing it will go back to new highs - 2M float so can have explosive moves at any time and they have real bitcoin mining operations across the US. $OBAI $CMND $RPGL $BRTX watch

0 · Reply

BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform

Apr 7, 2026, 8:15 AM EDT - 18 days ago

BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform

Mar 30, 2026, 8:00 AM EDT - 26 days ago

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Mar 19, 2026, 8:00 AM EDT - 5 weeks ago

BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Mar 5, 2026, 8:00 AM EST - 7 weeks ago

BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026

Feb 24, 2026, 8:30 AM EST - 2 months ago

BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

Feb 13, 2026, 8:30 PM EST - 2 months ago

BioRestorative Announces Closing of $5.0 Million Public Offering

Feb 11, 2026, 10:30 PM EST - 2 months ago

BioRestorative Announces Pricing of $5.0 Million Public Offering

Feb 11, 2026, 7:30 AM EST - 2 months ago

BioRestorative Announces Positive Outcome from Type B Meeting with FDA

Nov 12, 2025, 4:30 PM EST - 5 months ago

BioRestorative Therapies Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:30 AM EDT - 6 months ago

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

Oct 22, 2025, 9:35 AM EDT - 6 months ago

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

Oct 15, 2025, 9:35 AM EDT - 6 months ago

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

Oct 7, 2025, 9:25 AM EDT - 7 months ago

BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

Oct 6, 2025, 2:28 PM EDT - 7 months ago

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

Aug 12, 2025, 4:30 PM EDT - 9 months ago

BioRestorative Therapies Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:30 PM EDT - 9 months ago

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

Jun 18, 2025, 10:50 AM EDT - 11 months ago

BioRestorative Therapies Transcript: Status Update

Jun 18, 2025, 9:35 AM EDT - 11 months ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Jun 17, 2025, 9:25 AM EDT - 11 months ago

BioRestorative Announces Share Repurchase Program

Jun 13, 2025, 7:45 AM EDT - 11 months ago

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

Jun 9, 2025, 7:45 AM EDT - 11 months ago

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q1 2025

May 13, 2025, 9:15 AM EDT - 1 year ago

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

May 8, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025

May 7, 2025, 9:15 AM EDT - 1 year ago

BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025

Apr 15, 2025, 8:30 AM EDT - 1 year ago

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

Apr 10, 2025, 9:15 AM EDT - 1 year ago

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

Mar 27, 2025, 4:30 PM EDT - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q4 2024

Feb 27, 2025, 10:30 AM EST - 1 year ago

BioRestorative Therapies Transcript: Status Update

Feb 27, 2025, 9:45 AM EST - 1 year ago

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Feb 26, 2025, 8:15 PM EST - 1 year ago

BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

Dec 5, 2024, 6:45 AM EST - 1 year ago

BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program

Nov 13, 2024, 4:30 PM EST - 1 year ago

BioRestorative Therapies Earnings Call Transcript: Q3 2024

Nov 5, 2024, 7:10 AM EST - 1 year ago

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

Oct 3, 2024, 4:15 PM EDT - 1 year ago

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 19, 2024, 6:55 AM EDT - 1 year ago

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

Jul 23, 2024, 7:10 AM EDT - 1 year ago

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

Jun 27, 2024, 7:40 AM EDT - 1 year ago

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

Jun 17, 2024, 7:05 AM EDT - 2 years ago

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

Jun 13, 2024, 7:00 AM EDT - 2 years ago

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

Jun 4, 2024, 8:50 AM EDT - 2 years ago

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

May 24, 2024, 7:45 PM EDT - 2 years ago

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

May 15, 2024, 9:00 AM EDT - 2 years ago

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

May 14, 2024, 4:10 PM EDT - 2 years ago

BioRestorative Therapies Provides First Quarter 2024 Business Update

May 8, 2024, 7:30 AM EDT - 2 years ago

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

Apr 30, 2024, 4:15 PM EDT - 2 years ago

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 30, 2024, 7:30 AM EDT - 2 years ago

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

Apr 16, 2024, 7:45 AM EDT - 2 years ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

Apr 8, 2024, 7:45 AM EDT - 2 years ago

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Apr 3, 2024, 4:38 PM EDT - 2 years ago

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants

Apr 1, 2024, 7:45 AM EDT - 2 years ago

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Mar 11, 2024, 4:15 PM EDT - 2 years ago

BioRestorative Therapies to Participate in the 36th Annual ROTH Conference

Feb 14, 2024, 9:15 AM EST - 2 years ago

BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting

Feb 6, 2024, 8:05 AM EST - 2 years ago

BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market

_Burn_ Apr. 24 at 4:14 PM

$BRTX https://x.com/BioRestorative/status/2047674445515669998?s=20

0 · Reply

focafoca99 Apr. 23 at 9:33 PM

$BRTX updated its corporate presentation for use in investor meetings and conferences.

1 · Reply

MoonSprinkle Apr. 22 at 11:57 PM

$BRTX Positive clinical progress

2 · Reply

_Burn_ Apr. 22 at 2:45 PM

$BRTX https://x.com/BioRestorative/status/2046961905320014138?s=20

0 · Reply

Pamella3897 Apr. 22 at 1:43 PM

$BRTX !!!!!!

1 · Reply

DARKP00L Apr. 21 at 12:24 PM

$BRTX 08:06 on Apr. 21 2026 BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform #tradeideas

0 · Reply

MrTicker Apr. 21 at 12:06 PM

$BRTX BioRestorative Announces Strategic Partnership With David J. Goldberg, M.D. To Accelerate Market Adoption Of Its BioCosmeceutical Platform BENZINGA 7:06 AM ET 4/21/2026

0 · Reply

MrTicker Apr. 21 at 12:05 PM

0 · Reply

Pamella3897 Apr. 20 at 9:38 PM

$BRTX Post-Effective Amendment No. 1 to Form S-1 Up to 15,285,715 shares underlying warrants BUYER BEWARE!!! HUGE OFFERING IMMINENT!!!

1 · Reply

FillSniper42 Apr. 17 at 7:57 PM

0 · Reply

TaiJi_Kong Apr. 17 at 3:41 PM

$BRTX yesterday I learned in 2025, FDA approve a Phase 2 for Cervical Discogenic using BRTX-100. Anybody have any thoughts?

0 · Reply

FatherFauci Apr. 16 at 12:14 PM

$BRTX share selling scam. Need money to pay their rent so they're asking for a vote to sell more shares in anticipation of the next R/S. Bagholders vote no

1 · Reply

_Burn_ Apr. 15 at 8:57 PM

$BRTX https://x.com/BioRestorative/status/2044413348083863881?s=20

0 · Reply